COVID-19 and immune checkpoint inhibitors.

Ahmed, M S; Brehme, H; Friedrich, S; Reinhardt, L; Blum, S; Beissert, S; Meier, F

Ahmed, M S; Brehme, H; Friedrich, S; Reinhardt, L; Blum, S; Beissert, S; Meier, F.

Ahmed MS; Skin Cancer Center, University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany.
Brehme H; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Friedrich S; Department of Anesthesiology and Intensive Care, Emergency Medicine and Pain Therapy, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
Reinhardt L; Department of Anesthesiology and Intensive Care, Emergency Medicine and Pain Therapy, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
Blum S; Skin Cancer Center, University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany.
Beissert S; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Meier F; Institute and Polyclinic for Diagnostic and Interventional Radiology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

J Eur Acad Dermatol Venereol ; 35(5): e312-e314, 2021 May.

Article in English | MEDLINE | ID: covidwho-1494746

Subject(s)

COVID-19; Immune Checkpoint Inhibitors; Humans; Immunotherapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Checkpoint Inhibitors / COVID-19 Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2021 Document Type: Article Affiliation country: Jdv.17172

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google